Gain Therapeutics Inc (GANX) Stock Price, Quote & News

Company Profile

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 500 1556

Website: gaintherapeutics.com

Address:

4800 Montgomery Lane, Suite 220, Bethesda, United States

Jwa68 Apr. 5 at 3:00 PM

$GANX GT-00287 could be one of the most important and biggest selling drugs in history, excluding the back up compound and pipeline. Gain offers a literal franchise like opportunity on multiple targeted dieases beyond just PD, incliding Alzheimers. As a daily administered drug taken for life upon diagnosis, the market potential for just on-label use is staggering, let alone off-label. With now available early testing and screening, and critical biomarkers like those discovered by Gain, the disease can be caught far in advance of symptons becoming pronounced. Its likely ability to prempt the disease cascade affect may be close to a functional cure and could be a profalactic against the disease ever manifesting, while promoting better overall brain health, importantly improving mitochondrial and lysomal health. At some point soon, don't ne surprised when some in the scientific community stsrt to term it a possible better quality of life drug that may have anti-aging potential.

0 · Reply

microcapspeculator Apr. 5 at 1:51 PM

$GANX The numbers are truly staggering and this is just the US. Anyone wondering if GT-02287 will be sold too low just needs to step back and understand the potential impact of a drug that can just slow progression not reversing like we are seeing. New Report Finds Parkinson’s Disease Cost Patients, Families and the Federal Government $82.2 Billion in 2024 | Parkinson's Disease https://www.michaeljfox.org/news/new-report-finds-parkinsons-disease-cost-patients-families-and-federal-government-822-billion

0 · Reply

Buck619 Apr. 5 at 3:36 AM

$GANX I hopes some peoples brackets are jacked up. GoBlue!

0 · Reply

AtomBull27 Apr. 4 at 9:18 PM

$GANX Hoping there’s something juicy in the April corporate deck update. Probably not but gotta be getting close here to the financing deal…

0 · Reply

Pacsbull Apr. 4 at 7:12 PM

$GANX Can anyone explain to me what their reasoning may be to why we have an expected P2 start date but there’s no hiring happening? Does that not indicate they have confidence or at least are aware of options in regards how they are going to fund it?

1 · Reply

littlecjc016 Apr. 4 at 3:15 PM

$GANX All these cryptic messages…is something coming or is it all speculation? I saw that there was a decent swing on after hours on Thursday. Either way something is coming eventually, hopefully good days ahead.

1 · Reply

gatorsgrip Apr. 4 at 1:19 PM

$GANX Board be warned, another Jwa imposter, report/block: https://stocktwits.com/Jwa_681

1 · Reply

Jwa68 Apr. 4 at 1:01 PM

$GANX If I was going to bet against someone in the biotech space, it would never be Dr. Khalid Islam. His track record speaks for itself, loud and clear, just read it. Multiple pharma exits well into the billions with drugs that weren't nearly as valuable as the first disease modifying drug for PD, GT-00287. Rest assured, he is working tirelessly behind the scenes to advance GT-00287 and get it to patients who need it desperately. It is deeply personal for him and all involved. The shares have been temporarily manipulated at the hands of some, obfuscating the true progress behind the scenes, which all would expect to now be tangible. The scale should soon tip as those who know, confidently tell others. Recent posts here citing experts in the space now talking about GT-00287 is exactly what we want to see, fortuitous. The times are a changing and wealth is often created having foresight to invest in advance of broader awareness, often an inflection point. DYDD.

1 · Reply

microcapspeculator Apr. 4 at 1:01 PM

$GANX Here are all the recent analysts reports plus the AD/PD charts. Gain Therapeutics(GANX): Year End Analysts Reports: AD/PD Reports Continued Reversal In Parkinson’s UPDRS Scores https://gaintherapeutics.wordpress.com/2026/04/04/gain-therapeuticsganx-year-end-analysts-reports-ad-pd-reports-continued-reversal-in-parkinsons-updrs-scores/

1 · Reply

Mstngman99 Apr. 4 at 1:59 AM

$GANX Catching up on posts and I see some people out there doing math trying to add 30 days to March 12th and expecting news. Just remember that the FDA had a reduced staff during the 43-day government shutdown and a mountain of backlog to work through. I believe that the 30-day window will pass, Gene will keep his shirt buttoned, and we probably won’t see an immediate press release. That’s not a red flag, that’s just the FDA being the FDA right now. The IND is coming. Q2 is the realistic window. Just don’t expect this massive move up to happen on an expected regulatory checkpoint. If it’s delayed for more info or for FDA delay we won’t know the reasons. Be patient, we are still early. $25B in pharma M&A last week alone. I also see pharma as one of the best beneficiaries of AI from discovery to cost savings. Buying XBI as well.

1 · Reply

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

Mar 19, 2026, 4:57 PM EDT - 16 days ago

Gain Therapeutics to Present at the 38th Annual ROTH Conference

Mar 18, 2026, 8:15 AM EDT - 18 days ago

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

Mar 12, 2026, 7:00 AM EDT - 24 days ago

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

Feb 19, 2026, 7:00 AM EST - 6 weeks ago

Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Jan 7, 2026, 7:00 AM EST - 3 months ago

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Jan 6, 2026, 7:00 AM EST - 3 months ago

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

Dec 18, 2025, 4:05 PM EST - 3 months ago

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease

Dec 18, 2025, 7:00 AM EST - 3 months ago

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease

Nov 20, 2025, 7:00 AM EST - 4 months ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

Nov 12, 2025, 7:00 AM EST - 5 months ago

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 7, 2025, 4:16 AM EST - 5 months ago

Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients

Oct 30, 2025, 7:00 AM EDT - 5 months ago

Gain Therapeutics to Present at Neuroscience 2025

Oct 16, 2025, 7:00 AM EDT - 6 months ago

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

Oct 6, 2025, 8:15 AM EDT - 6 months ago

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®

Sep 23, 2025, 7:40 AM EDT - 6 months ago

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

Sep 18, 2025, 7:41 AM EDT - 7 months ago

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease

Sep 4, 2025, 8:00 AM EDT - 7 months ago

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Aug 12, 2025, 7:00 AM EDT - 8 months ago

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

Jul 24, 2025, 8:53 AM EDT - 9 months ago

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

Jul 16, 2025, 9:03 AM EDT - 9 months ago

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

Jul 15, 2025, 4:36 PM EDT - 9 months ago

Gain Therapeutics Announces Proposed Public Offering

Jun 30, 2025, 4:05 PM EDT - 9 months ago

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

Jun 10, 2025, 8:00 AM EDT - 10 months ago

Gain Therapeutics to Participate in Upcoming Investor Conferences

May 29, 2025, 8:45 AM EDT - 11 months ago

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

May 14, 2025, 7:30 AM EDT - 11 months ago

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

May 12, 2025, 7:30 AM EDT - 11 months ago

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

May 1, 2025, 7:30 AM EDT - 1 year ago

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

Apr 30, 2025, 7:45 AM EDT - 1 year ago

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

Mar 14, 2025, 7:45 AM EDT - 1 year ago

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

Mar 6, 2025, 7:55 AM EST - 1 year ago

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

Feb 6, 2025, 8:45 AM EST - 1 year ago

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

Feb 5, 2025, 8:30 AM EST - 1 year ago

Gain Therapeutics To Participate in Upcoming Investor Conferences

Dec 31, 2024, 12:23 PM EST - 1 year ago

Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results

Dec 23, 2024, 7:30 AM EST - 1 year ago

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease

Dec 11, 2024, 8:30 AM EST - 1 year ago

Gain Therapeutics To Present At Biotech Showcase 2025

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

Oct 3, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Participate at Upcoming Investor Conferences

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Aug 29, 2024, 7:30 AM EDT - 1 year ago

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease

Jul 1, 2024, 10:13 AM EDT - 1 year ago

Gain Therapeutics, Inc. (GANX) Special Call Transcript

Jun 28, 2024, 4:39 PM EDT - 1 year ago

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

Jun 27, 2024, 4:08 PM EDT - 1 year ago

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Jun 27, 2024, 8:35 AM EDT - 1 year ago

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease

Jwa68 Apr. 5 at 3:00 PM

0 · Reply

microcapspeculator Apr. 5 at 1:51 PM

0 · Reply

Buck619 Apr. 5 at 3:36 AM

$GANX I hopes some peoples brackets are jacked up. GoBlue!

0 · Reply

AtomBull27 Apr. 4 at 9:18 PM

$GANX Hoping there’s something juicy in the April corporate deck update. Probably not but gotta be getting close here to the financing deal…

0 · Reply

Pacsbull Apr. 4 at 7:12 PM

1 · Reply

littlecjc016 Apr. 4 at 3:15 PM

1 · Reply

gatorsgrip Apr. 4 at 1:19 PM

$GANX Board be warned, another Jwa imposter, report/block: https://stocktwits.com/Jwa_681

1 · Reply

Jwa68 Apr. 4 at 1:01 PM

1 · Reply

microcapspeculator Apr. 4 at 1:01 PM

1 · Reply

Mstngman99 Apr. 4 at 1:59 AM

1 · Reply

Jwa68 Apr. 3 at 11:31 PM

$GANX $AI Glad to have your here @PaulThomasTPG. Nice to see the channel approaching almost 60k subscribers and your coverage of Gain. Your audience could be a part of something really special with it, especially from this level. Keep up the good work.

1 · Reply

Pacsbull Apr. 3 at 10:31 PM

$GANX Why the sudden cryptic posts alluding to some development were not aware of?

1 · Reply

YoloAlfred Apr. 3 at 9:26 PM

$GANX Guys and gals i know long suffering really well...I held ESPR...for four years...Roller coaster from hell having a person pondering hiring a hitman to all sorts of emotions. Im going to dig in on this one over the next 5 days

1 · Reply

PaulThomasTPG Apr. 3 at 8:54 PM

$GANX April will be a good month for GANX, its too beat down recently. Opportuniues here and in $AI too https://youtu.be/dnlkqV-Kb6g

1 · Reply

YoloAlfred Apr. 3 at 6:10 PM

$GANX Catalyst soon

1 · Reply

gatorsgrip Apr. 3 at 4:36 PM

$GANX Thought I'd reshare this post. Great pts. of wisdom in dealing with bios and trading in general. BEST TO EVERYONE and have a good EASTER!!

0 · Reply

microcapspeculator Apr. 3 at 4:30 PM

$GANX When industry experts start mentioning GT-02287 its a very good sign. Not only as a treatment but also the validity as GCase as a target. The industry is shifting our way.

2 · Reply

Jwa68 Apr. 3 at 3:33 PM

$GANX

1 · Reply

microcapspeculator Apr. 3 at 2:53 PM

$GANX Plenty of cash to go around and activty does seem to be picking up. Just a matter of time before neurological space gets some interest. Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts - BioSpace https://www.biospace.com/business/pharmas-m-a-train-is-on-track-for-record-highs-with-more-deals-to-come-analysts Despite the sudden rush, BMO suspects that pharma is likely not done. The firm named Amgen, which has $18.6 billion in capacity, as well as AbbVie with $33.6 billion, BMS with $21.9 billion and Novartis with $53 billion, as high potential acquirers.

0 · Reply

microcapspeculator Apr. 3 at 2:01 PM

$GANX Correcting neuronal dysfunction is incredible but you can bet big pharma is going to verify. It's that big of deal. CSF Biomarker May Support Lewy Body Diagnosis https://conexiant.com/neurology/articles/csf-biomarker-may-support-lewy-body-diagnosis/ DDC plays a key role in dopamine synthesis, and the researchers proposed that elevated CSF concentrations may reflect dopaminergic neuronal dysfunction or degeneration, although the precise mechanism remains uncertain. The findings suggest that CSF DDC may serve as a supportive biomarker to aid in the diagnosis and biological characterization of Lewy body disorders in clinical and research settings. However, further studies are needed to evaluate performance in broader and longitudinal patient populations and across disease stages.

0 · Reply

mwb1 Apr. 3 at 12:25 PM

$GANX Good find-- this is an insightful article and the discussion around Parkinson’s treatments and the debate around how to define “disease-modifying” is especially relevant to us. There is clearly ambiguity here among experts on how to weight the three different ways to frame disease-modification: sustained clinical benefit, reduced need for symptomatic therapies, and changes in underlying biology. 2287 is showing all three. The two therapies it mentions, AC Immune’s VacSyn and Roche’s Prasinezumab show their strongest evidence in the “changes in underlying biology”, but the other two categories are either fails or weak evidence. Gain has shown a clear way to stratify the patients—another topic where other treatments have failed—and in the high GluSph group, 2287 has shown stronger results in all three categories than Roche’s and AC Immune’s treatments, IMO. Gain just needs to show continued durability, and they’ll be way ahead of every other treatment— it won’t even be close.

1 · Reply

YoloAlfred Apr. 3 at 11:56 AM

$GANX How is your trading going🤦‍♂️

0 · Reply

Market Cap	78.15M
Revenue (ttm)	0.00
Net Income (ttm)	-20.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.02

Volume	522,900
Avg Vol	721,612
Day's Range	N/A - N/A
Shares Out	42.24M
Stochastic %K	33%
Beta	0.11
Analysts	Strong Sell
Price Target	$7.60